Search

Displaying results 1731 - 1740 of 4233 in total
  1. Drug

    Etilefrine

    go.drugbank.com/drugs/DB08985
    ApprovedWithdrawn

    It has been used as a vasoconstrictor agent.

  2. Drug

    Canrenoic acid

    go.drugbank.com/drugs/DB09015
    ApprovedInvestigationalWithdrawn

    Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

  3. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.

  4. Drug

    Trovafloxacin

    go.drugbank.com/drugs/DB00685
    ApprovedWithdrawn

    Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the a...

  5. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    The transmission of cytomegalovirus infection requires intimate contact with infected excretions such as saliva, urine, cervical and vaginal excretions, semen, breast milk and blood [L2228]. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].

  6. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    It is marketed as Vexol.

  7. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050,L64051] It is administered as a single, one-time intravenous infusion.

  8. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.

  9. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]

  10. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation